Procter & Gamble Hygiene and Health Care Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Procter & Gamble Hygiene and Health Care Ltd trades at ₹8,721, in a downtrend and 87 weeks into that stage. That is −20.2% against its own 200-day average. It sits at 0% of a 52-week range of ₹8,721 to ₹14,337. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (41 weeks and counting).

Today the stock is in a downtrend — week 87 of stage 4, confirmed. At ₹8,721 it trades −20.2% versus its 200-day average and sits at 0% of its 52-week range (₹8,721–₹14,337).

Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +39% while the NIFTY 500 moved +274% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (41 weeks and counting; last ahead the week of 2025-10-24) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 1st percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Procter & Gamble Hygiene and Health Care Ltd trades at 34.0× P/E, about the cheapest it has ever traded. Its long-run median P/E is 73.4×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 34.0× is about the cheapest it has ever traded, against a long-run median of 73.4× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +34.5% against a −34.5% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 5y, of the −7.5%/yr price move, ~+5.0%/yr came from earnings growth and ~−12.5 pp from the multiple (compressing); over 10y, of the +3.3%/yr price move, ~+7.4%/yr came from earnings growth and ~−4.1 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Procter & Gamble Hygiene and Health Care Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE lifting at 136.6% — the per-curve reads carry the story. The read is built from 12 quarters across 4 curves, on full evidence.

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

62.8/100 — rank 3 of 12 in FMCG - Personal Care · 90% evidence confidence

Procter & Gamble Hygiene and Health Care Ltd scores 62.8 out of 100 against the 12 companies it is compared with in FMCG - Personal Care, ranking 3. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 22.7 + 21.4 + 14.3 + 4.4 = 62.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Procter & Gamble Hygiene and Health Care Ltd reported ₹941 Cr of revenue in the Mar 26 quarter, −5.1% year on year. Over 10 years it has compounded at 6.5% a year. The last full year, Mar 26, came in at ₹4,290 Cr. The last four reported quarters add to ₹4,290 Cr.

Procter & Gamble Hygiene and Health Care Ltd reported ₹941 Cr of revenue in the Mar 26 quarter, −5.1% year on year. Over 10 years it has compounded at 6.5% a year. The last full year, Mar 26, came in at ₹4,290 Cr. The last four reported quarters add to ₹4,290 Cr.

Mar 26 revenue came in at ₹4,290 Cr (+27.1% on the year), capping 10 years at 6.5% compound. The latest quarter (Mar 26) printed ₹941 Cr, −5.1% year on year.

Pace check: the last four quarters averaged −0.5% growth against the decade's 6.5% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew −0.4% over the last 4 quarters against +2.0%/yr over the last 8 — stabilising; TTM profit +19.2% vs +7.2%/yr — accelerating.

→ Revenue slipped — did margins hold as it scaled? Next: 23.0% this quarter (+2.0 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Procter & Gamble Hygiene and Health Care Ltd's operating margin is 23.0% in the Mar 26 quarter, +2.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 20.0% to 29.0%. The current quarter sits inside that band.

Procter & Gamble Hygiene and Health Care Ltd's operating margin is 23.0% in the Mar 26 quarter, +2.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 20.0% to 29.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 23.0%, +2.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 20.0%–29.0%.

Why the margin moved: operating margin went +2.1 pp year on year while gross margin went +1.9 pp — the gain came mostly from the gross line: input costs and pricing.

→ Margins held — did that reach the bottom line? Next: profit −1.9% in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Procter & Gamble Hygiene and Health Care Ltd earned ₹153 Cr of net profit in the Mar 26 quarter, −1.9% year on year. Full-year Mar 26 profit was ₹856 Cr. The 10-year compound rate is 7.3%. That is 16.3% of the quarter's revenue. The same quarter a year earlier earned ₹156 Cr.

Procter & Gamble Hygiene and Health Care Ltd earned ₹153 Cr of net profit in the Mar 26 quarter, −1.9% year on year. Full-year Mar 26 profit was ₹856 Cr. The 10-year compound rate is 7.3%. That is 16.3% of the quarter's revenue. The same quarter a year earlier earned ₹156 Cr.

Mar 26 profit was ₹153 Cr, −1.9% year on year. On the full year, Mar 26 printed ₹856 Cr (+34.4%), and the 10-year compound rate is 7.3%.

🚨 Why profit moved: revenue contributed −5.1% and the margin +2.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +36.5% vs revenue −0.5%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

→ Profit rose — but did the cash follow? Next: 92% of the last 3 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 92% of Procter & Gamble Hygiene and Health Care Ltd's reported profit arrived as operating cash — the cash follows the profit. In Mar 26 that was ₹924 Cr of operating cash against ₹856 Cr of profit. After ₹49.0 Cr of capital spending, ₹875 Cr was left as free cash.

Mar 26: operating cash of ₹924 Cr against reported profit of ₹856 Cr, leaving free cash of ₹875 Cr after ₹49.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 92% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 92%: the cash cycle stretched 18 days between FY21 and Mar 26 — more of each rupee of profit waits inside the cycle before arriving.

Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.

→ So follow the cash to where it goes. Next: a −126-day cycle and ₹122 Cr of building.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Procter & Gamble Hygiene and Health Care Ltd's cash conversion cycle runs −126 days in Mar 26, up from −144 days in FY21. Capital spending ran ₹122 Cr over the last 3 years. At Mar 26 sales of ₹4,290 Cr each day of that cycle holds about ₹11.8 Cr, so roughly ₹−1,481 Cr sits inside the business at any moment.

Mar 26: debtors at 21 days, inventory at 51 days — roughly 1.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −126 days, looser than FY21's −144.

The full loop: cash goes out to suppliers and production on day 0; stock waits 51 days to sell; customers pay about 21 days after that; and suppliers themselves are paid at 197 days — netting out to the −126-day cycle.

In money terms: at Mar 26 sales of ₹4,290 Cr, each day of the cycle holds about ₹11.8 Cr — so the −126-day loop keeps roughly ₹−1,481 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹122 Cr over the last 3 fiscal years against ₹151 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹21.0 Cr (Mar 26) — capacity paid for but not yet earning.

The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 157% and the ROIC − WACC spread is +497.6 pp.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Procter & Gamble Hygiene and Health Care Ltd earns a ROCE of 157% in Mar 26. That is up from a trough of 45% in FY16. Return on invested capital clears the cost of that capital by +497.6 percentage points, so growth here adds value rather than only size.

Mar 26 ROCE is 157%, recovered from a FY16 trough of 45% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (Mar 26): 20.0% net margin × 2.38× asset turns × 2.40× balance-sheet leverage ≈ 114.2% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 509.6% − 12.0% = a +497.6 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.00.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Procter & Gamble Hygiene and Health Care Ltd carries total debt of ₹1.0 Cr against shareholder equity of ₹753 Cr as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.00 in FY22 to 0.00 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of ₹1.0 Cr against shareholder equity of ₹753 Cr — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.00 (FY22) to 0.00 (FY26). The returns on this page are earned, not borrowed.

→ Who owns this, and are they adding or leaving? Next: the register is quiet.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

No holder of Procter & Gamble Hygiene and Health Care Ltd moved a full percentage point over the last two years — the register is quiet. Domestic institutions moved +0.4 points over the same window, to 15.6%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Foreign institutions: −0.6 points over 8 quarters to 1.0%; Domestic institutions: +0.4 points over 8 quarters to 15.6%; Promoters: +0.0 points over 8 quarters to 70.6%.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Procter & Gamble Hygiene and Health Care Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions